Cancer drug developer brings in $52M from stock sale

Verastem, which specializes in drugs that target cancer stem cells, secured at least $52 million from a public stock offering. The Cambridge, Mass.-based firm will use the money mainly to support studies of its lead drug candidates for cancer.

View Full Article in:

American City Business Journals · Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ